Galderma Group AG (GDERF)
| Market Cap | 45.42B +8.7% |
| Revenue (ttm) | 5.92B +26.3% |
| Net Income | 863.00M +128.3% |
| EPS | 3.65 +129.8% |
| Shares Out | n/a |
| PE Ratio | 52.63 |
| Forward PE | 34.36 |
| Dividend | 0.45 (0.24%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 11,881 |
| Open | 204.20 |
| Previous Close | 191.38 |
| Day's Range | 187.77 - 204.20 |
| 52-Week Range | 167.00 - 248.46 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 23, 2026 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 19... [Read more]
Financial Performance
In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.
Financial StatementsNews
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Acad...
Galderma mindful of focus while eyeing product range expansion, CEO tells FuW
Galderma's CEO said the Swiss skincare firm plans to expand its product range at some point but would remain cautious not to lose its focus, speaking in an interview with Swiss newspaper Finanz und...
Galderma's Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patie...
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin reg...
Galderma Group AG Earnings Call Transcript: Q2 2026
Record H1 2026 net sales of $3.1B, up 24.6% year-on-year, with strong double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and full-year guidance was raised to 19%-21% net sales growth, with Nemluvio on track for $1B in sales.
Galderma Group AG Earnings release: Q2 2026
Galderma Group AG released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Galderma Group AG Quarterly report: Q2 2026
Galderma Group AG has published its Q2 2026 quarterly earnings report on July 23, 2026.
Galderma Group AG Slides: Q2 2026
Galderma Group AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report takin...
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 b...
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC re...
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA wit...
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the ...
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differ...
Galderma Group AG Earnings Call Transcript: Q1 2026
Q1 2026 net sales rose 25.5% year-over-year to $1.473 billion, with double-digit growth across all segments and geographies. Full-year guidance for 17%-20% net sales growth and ~26% EBITDA margin is confirmed, supported by strong Dermatological Skincare and NEMLUVIO performance.
Galderma Group AG Earnings release: Q1 2026
Galderma Group AG released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Galderma Group AG Slides: Q1 2026
Galderma Group AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the yea...
Galderma Shareholders Approve All Annual General Meeting Proposals
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at ...
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Ala...
Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare
MIAMI--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, ...
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American A...
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollow...
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which ...